Company Filing History:
Years Active: 2023
Title: Innovations of Jonathan Patrick Lowther
Introduction
Jonathan Patrick Lowther is an accomplished inventor based in Abingdon, GB. He has made significant contributions to the field of immunotherapy, particularly in the development of T cell receptors that target specific tumor antigens. His work is pivotal in advancing treatments for malignant diseases.
Latest Patents
One of his notable patents is titled "T cell receptors specific for the NY-ESO-1 tumor antigen-HLA-A*02 complex." This invention relates to T cell receptors (TCRs) that bind the HLA-A*02 restricted peptide SLLMWITQC derived from the cancer antigen NY-ESO-1. The TCRs may include mutations within the alpha and/or beta variable domains compared to a native NY-ESO-1 TCR. These TCRs are particularly suitable for use as novel immunotherapeutic reagents for treating malignant diseases. He holds 1 patent in this area.
Career Highlights
Jonathan is associated with Immunocore Limited, a company that focuses on developing innovative therapies for cancer and other diseases. His work at Immunocore has been instrumental in pushing the boundaries of cancer treatment through targeted immunotherapy.
Collaborations
He has collaborated with notable colleagues, including Fiona Chester and Andrew Alexander Knox, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Jonathan Patrick Lowther's contributions to the field of immunotherapy through his innovative patents and collaborations highlight his role as a key figure in advancing cancer treatment. His work continues to inspire future developments in medical science.